A practical reference on circadian rhythm: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Feline cutaneous asthenia is a rare inheritable skin disease of cats characterised by abnormal elasticity, stretching, and improper healing of the skin. Pendulous wing-like folds of skin form on the cat's back, shoulders and haunches. Even stroking the cat can cause the skin to stretch and tear. A recessive autosomal (non-sex linked) form of feline cutaneous asthenia has been identified in Siamese cats and related breeds. In the homozygous state, it is apparently lethal. Feline cutaneous asthenia is similar to the Ehlers–Danlos syndrome of humans. Cats with cutaneous asthenia cannot be grasped by the scruff, as this may tear away. Cats may also have slipping joints, as in human Ehlers-Danlos syndrome. Dietary supplements may be needed to promote skin healing and regrowth.
== Mechanism == The protein obeys Michaelis-Menton kinetics and has an associated KM of 278 ± 49 μM. The GYDQL and YFPQA motifs on the C-terminal binds cystinosin to the lysosome. Mutations in the GYDQL motif cause a repositioning of cystinosin to being partially on the plasma membrane and partially on the lysosome. Mutations in both GYDQL and YFPQA motifs cause cystinosin to position itself to the plasma membrane instead of lysosomes An increase in acidity in the lumen of the lysosome initiates the reaction of CySS and H+ being transported into the cytosol.
=== Structure === The proton pump, H+/K+ ATPase is a α,β-heterodimeric enzyme. The catalytic α subunit has ten transmembrane segments with a cluster of intramembranal carboxylic amino acids located in the middle of the transmembrane segments TM4, TM5, TM6 and TM8. The β subunit has one transmembrane segment with N terminus in cytoplasmic region. The extracellular domain of the β subunit contains six or seven N-linked glycosylation sites which is important for the enzyme assembly, maturation and sorting.
Sources: en.wikipedia.org
=== Home ground and training base === Essendon's primary home ground was Windy Hill Oval, where the club played home matches from 1922 to 1991. Prior to this, the club played at the defunct East Melbourne Cricket Ground. In 1992, the club ceased playing senior matches at Windy Hill and moved games to the Melbourne Cricket Ground (MCG). In 2000, the club shifted the majority of its home games to the newly constructed Docklands Stadium, while retaining high-drawing fixtures at the MCG. This arrangement usually resulted in seven games at Docklands and four at the MCG, though in 2026, the club succeeded in persuading the AFL to fixture an additional home game at the MCG, resulting in six at Docklands Stadium and five at the MCG. Since 2013 the Essendon Football Club's primary training and administration base has been at The Hangar, a purpose-built training facility located in Melbourne Airport. Prior to this Essendon was based at the club's long-standing home ground of Windy Hill Oval.
== Medicinal properties == Mashua has putative anaphrodisiac effects. It has been recorded by the Spanish chronicler Cobo that mashua was fed to their armies by the Inca Emperors, "that they should forget their wives". Studies of male rats fed on mashua tubers have shown a 45% drop in testosterone levels due to the presence of isothiocyanates. Mashua contains docosatetraenoylethanolamide, a cannabinoid structurally similar to anandamide that also acts on the cannabinoid (CB1) receptor among other structurally related compounds such as N–oleoyldopamine. Topical mashua in a 1% gel formulation has proven to increase the healing activities of open wounds in mice populations. Further studies are necessary to determine potential wound healing success for human application.
Grilled cold noodles (Chinese: 烤冷面; pinyin: kǎolěngmiàn) is a local specialized snack of the Chinese province of Heilongjiang. It is also used as a side dish, usually sold at night markets or roadside stands rather than in restaurant chains. Grilled cold noodles are usually cooked with noodles that somewhat resemble pieces of paper, and with eggs, onions, and other auxiliary materials, The main condiment is sweet bean sauce or gochujang. Traditionally, there are three different ways to cook the dish: grilling, teppanyaki and frying.
==== Mechanical exfoliation ==== Geim and Novoselov initially used adhesive tape to pull graphene sheets away from graphite. Achieving single layers typically requires multiple exfoliation steps. After exfoliation, the flakes are deposited on a silicon wafer. Crystallites larger than 1 mm and visible to the naked eye can be obtained. As of 2014, exfoliation produced graphene with the lowest number of defects and highest electron mobility. One specific exfoliation technique involved using a sharp single-crystal diamond wedge to penetrate the graphite source and precisely cleave individual layers. That same year, researchers also developed liquid-phase methods, creating defect-free, unoxidized graphene-containing liquids from graphite using mixers that generate extremely high local shear rates greater than 10×104. A 2014 study published in Nature Materials demonstrated that scalable production of defect-free graphene is possible through shear exfoliation using a high-shear mixer. This technique can produce large quantities of few-layer graphene in solution while preserving structural integrity. As turbulence is not necessary for mechanical exfoliation, resonant acoustic mixing or low-speed ball milling can also be effective in the production of high-yield and water-soluble graphene.
Sources: en.wikipedia.org
The CompTox Chemicals Dashboard is a freely accessible online database created and maintained by the U.S. Environmental Protection Agency (EPA). The database provides access to multiple types of data including physicochemical properties, environmental fate and transport, exposure, usage, in vivo toxicity, and in vitro bioassay. EPA and other scientists use the data and models contained within the dashboard to help identify chemicals that require further testing and reduce the use of animals in chemical testing. The Dashboard is also used to provide public access to information from EPA Action Plans, e.g. around perfluorinated alkylated substances. Originally titled the Chemistry Dashboard, the first version was released in 2016. The latest release of the database (version 3.0.5) contains manually curated data for over 875,000 chemicals and incorporates the latest data generated from the EPA's Toxicity Forecaster (ToxCast) high-throughput screening program. The Chemicals Dashboard incorporates data from several previous EPA databases into one package including the ToxCast Dashboard, the Endocrine Disruption Screening Program (EDSP) Dashboard and the Chemical and Products Database (CPDat).
This difference was characterised by an attenuated EEG power density within slow frequencies (<4 Hz) following flmodafinil treatment, though both compounds increased power density relative to placebo. In contrast to modafinil, flmodafinil is not an inducer of the cytochrome P450 CYP3A4 or CYP3A5 enzymes.
==== sera-serp ==== seractide (INN) seratrodast (INN) Serax serazapine (INN) Serc Serdaxin serdemetan (INN) serelaxin (INN) Serentil Serevent serfibrate (INN) sergliflozin (USAN) sergolexole (INN) seridopidine (INN) serine (INN) serlopitant (USAN) sermetacin (INN) sermorelin (INN) Seromycin Serophene Seroquel Serostim Serpalan Serpanray Serpasil Serpatabs Serpate Serpivite serplulimab (INN)
=== Proteins === The chromatographic purification of proteins from complex mixtures can be quite challenging, particularly when the mixtures contain similarly retained proteins or when it is desired to enrich trace components in the feed. Further, column loading is often limited when high resolutions are required using traditional modes of chromatography (e.g. linear gradient, isocratic chromatography). In these cases, displacement chromatography is an efficient technique for the purification of proteins from complex mixtures at high column loadings in a variety of applications. An important advance in the state of the art of displacement chromatography was the development of low molecular mass displacers for protein purification in ion exchange systems. This research was significant in that it represented a major departure from the conventional wisdom that large polyelectrolyte polymers are required to displace proteins in ion exchange systems. Low molecular mass displacers have significant operational advantages as compared to large polyelectrolyte displacers. For example, if there is any overlap between the displacer and the protein of interest, these low molecular mass materials can be readily separated from the purified protein during post-displacement processing using standard size-based purification methods (e.g. size exclusion chromatography, ultrafiltration). In addition, the salt-dependent adsorption behavior of these low MW displacers greatly facilitates column regeneration.
Although most serpins control proteolytic cascades, some proteins with a serpin structure are not enzyme inhibitors, but instead perform diverse functions such as storage (as in egg white—ovalbumin), transport as in hormone carriage proteins (thyroxine-binding globulin, cortisol-binding globulin) and molecular chaperoning (HSP47). The term serpin is used to describe these members as well, despite their non-inhibitory function, since they are evolutionarily related.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.